A comparison of progestogens or oral contraceptives and gonadotropin-releasing hormone agonists for the treatment of endometriosis: a systematic review
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This systematic review examined the use of progestogens or oral contraceptives and gonadotropin-releasing hormone (GnRH) agonists for the treatment of endometriosis. RESEARCH DESIGN AND METHODS: Inclusion criteria were: i) randomized controlled trials (RCTs); ii) comparison of progestogens with GnRH agonists for treatment of endometriosis; and iii) endometriosis diagnosed by laparoscopy or laparotomy. MAIN OUTCOME MEASURES: Pelvic pain, bone mineral density, serum estradiol level, and side effects. RESULTS: Of 128 articles identified, there were four RCTs comparing the use of progestogens and GnRH agonists. In three studies a progestogen (gestrinone, lynestrenol, or dienogest) was compared with leuprolide. In one study, ethinyl estradiol/norethindrone was compared with leuprolide/norethindrone. A meta-analysis was not possible as the studies varied markedly in their protocols, inclusion criteria, and the drugs and doses administered. Leuprolide was as effective as gestrinone, dienogest, and continuous oral contraceptives (OCs) for the relief of endometriosis-related pain, whereas it was superior to lynestrenol. Leuprolide was associated with a significant reduction in bone mineral density and estradiol levels and a higher incidence of hot flushes, headaches, mood changes, and vaginal dryness, whereas progestogens were associated with higher incidences of weight gain and acne. CONCLUSIONS: These results suggest that progestogens or OCs may be used as first-line therapy for endometriosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comparative reliability and validity of chronic pain intensity measures.
Jensen, M. P., Turner, J. A., Romano, J. M., & Fisher, L. D. (1999) · Pain · doi:10.1016/s0304-3959(99)00101-3 · Cited by 1,247 · cited 1×
“Biberoglu and Behrman pain scores [15], numerical rating scores [16], and Beck Depression Inventory scores [17] all decreased from baseline values in both groups after treatment; however, in the extent of reduction in these measures between the groups were not different.”
BackgroundRecurrence of endometriosis and its control
Guo, S.-W. (2009) · Human Reproduction Update · doi:10.1093/humupd/dmp007 · Cited by 719
Dosage aspects of danazol therapy in endometriosis: Short-term and long-term effectiveness
Biberoglu, K. O., & Behrman, S. J. (1981) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(81)90478-6 · Cited by 267
Progestagens and anti-progestagens for pain associated with endometriosis
Brown, J., Kives, S., & Akhtar, M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002122.pub2 · Cited by 250
Strowitzki, T., Faustmann, T., Gerlinger, C., & Seitz, C. (2010) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2010.04.002 · Cited by 227 · cited 1×
“[21] reported that dienogest at a dosage of 2 mg per day for 12 weeks was more effective than placebo at reducing endometriosis-related pain.”
BackgroundVERCELLINI, P., DE MATTEIS, S., SOMIGLIANA, E., BUGGIO, L., FRATTARUOLO, M. P., & FEDELE, L. (2013) · Acta Obstetricia et Gynecologica Scandinavica · doi:10.1111/j.1600-0412.2012.01470.x · Cited by 115
Gonadotropin-releasing hormone agonist and add-back therapy: what do the data show?
Surrey, E. S. (2010) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e32833b35a7 · Cited by 64
Cited by
Endometriosis is a chronic systemic disease: Clinical challenges and novel innovations
Taylor, H. S., Kotlyar, A. M., & Flores, V. A. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00389-5 · Cited by 1,425
Estrogen-progestins and progestins for the management of endometriosis
Vercellini, P., Buggio, L., Berlanda, N., Barbara, G., Somigliana, E., & Bosari, S. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.10.022 · Cited by 243
Guerriero, S., Ajossa, S., Orozco, R., Perniciano, M., Jurado, M., Melis, G. B., & Alcazar, J. L. (2016) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.15662 · Cited by 167
Continuous versus cyclic oral contraceptives for the treatment of endometriosis: a systematic review
Zorbas, K. A., Economopoulos, K. P., & Vlahos, N. F. (2015) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-015-3641-1 · Cited by 114
“Recently, dienogest has been proposed as a firstline treatment for endometriosis, and its use is increasing even if it is much more expensive than oCP [22].”
BackgroundDienogest in the treatment of endometriosis
Bizzarri, N., Remorgida, V., Leone Roberti Maggiore, U., Scala, C., Tafi, E., Ghirardi, V., Salvatore, S., Candiani, M., Venturini, P. L., & Ferrero, S. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.943734 · Cited by 63
Metadata
- Authors
- Jeng, C.-J., Chuang, L., & Shen, J.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa UK Limited
- Published
- 2014-03-04
- Volume
- 15
- Issue
- 6
- Pages
- 767-773
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2044647590
- Cited by
- 36
- References
- 7
- FWCI
- 0.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A comparison of progestogens or oral contraceptives and gonadotropin-releasing hormone agonists for the treatment of endometriosis: a systematic review. https://app.cochat.ai/papers/10.1517/14656566.2014.888414
- The paper
- Jeng, C.-J., Chuang, L., & Shen, J. (2014). A comparison of progestogens or oral contraceptives and gonadotropin-releasing hormone agonists for the treatment of endometriosis: a systematic review. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.2014.888414
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.